According to the Business Service Bureau of Hengqin Guangdong Macao Deep Cooperation Zone (hereinafter referred to as the "Cooperation Zone"), recently, Hong Kong Lingnan Pharmaceutical Co., Ltd. cross-border commissioned Guangdong Macao Pharmaceutical Co., Ltd. (hereinafter referred to as "Guangdong Macao Pharmaceutical") to produce the traditional topical Chinese medicine preparation "Xiangsong Tongluo Oil", which has been officially approved for market and sold nationwide. This achievement is the first commissioned production case of drugs from Hong Kong and Macau to be implemented in the cooperation zone since the implementation of the "Implementation Plan for Supporting Hong Kong and Macau Drug Marketing Authorization Holders to Produce Drugs in 9 Mainland Cities of the Greater Bay Area" (hereinafter referred to as the "Implementation Plan"). Since March 1, 2024, the cooperation zone has provided a unique development platform for pharmaceutical companies in Hong Kong and Macau through the sub line management model of "opening up the first line and regulating the second line", becoming a "policy highland" and "industrial hotspot" for pharmaceutical production in Hong Kong and Macau. The successful implementation of the first mainland listed Hong Kong and Macau drug commissioned production project in the cooperation zone has solved the four major pain points of mainland production of Hong Kong and Macau drugs. Firstly, commissioned production does not require enterprises to build their own factories, and the landing production of products has been accelerated; The second is to efficiently integrate resources and reduce enterprise costs; The third is to achieve precise connection of standards; The fourth is to implement parallel priority review and synchronous approval to save approval time. Mr. Lv Weiqiang, CEO of Lingnan Pharmaceutical Factory in Hong Kong, President of the Hong Kong Chinese Pharmaceutical Association, and Chairman of the Hong Kong Chinese Medicine Association, said that the factory chose Hengqin and Guangdong Macao Pharmaceutical Industry precisely because of the dual certainty of "policy+industry" here. The relevant person in charge of the Business Service Bureau of the Cooperation Zone stated that with the deepening of the Implementation Plan, the Cooperation Zone will further play the role of a "super contact person" in the future, fully promote the production of Hengqin drugs in Hong Kong and Macao, help create an innovative highland for the pharmaceutical industry, and inject new impetus into the integrated development of the Guangdong Hong Kong Macao Greater Bay Area. (New Society)